Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Inclusion Criteria

• Those individuals over the age of 18 who are considering pancreatic cancer screening and meet any of the screening guidelines (National Comprehensive Cancer Network [NCCN] version 2.2022, dated 09 March 2022) below are eligible to participate in the study
• Individuals with pathogenic/likely pathogenic germline variants in STK11, and age >= 30 years. OR
• Individuals with pathogenic/likely pathogenic germline variants in CDKN2A, and age ≥ 40 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier). OR
• Individuals with pathogenic/likely pathogenic germline variants in one of the other pancreatic cancer susceptibility genes (ATM, BRCA1, BRCA2, MLH1, MSH2, MSH6, EPCAM, PALB2, TP53), and age >= 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) AND * Exocrine pancreatic cancer in >= 1 first- or second-degree relative from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. OR
• Individuals with pathogenic/likely pathogenic variants in PRSS1 AND a clinical phenotype consistent with hereditary pancreatitis, and age ≥40 years (or 20 years after onset of pancreatitis, whichever is earlier). OR
• Individuals with familial pancreatic cancer including: * Family history of exocrine pancreatic cancer in >= 2 first-degree relatives from the same side of the family, even in the absence of a known pathogenic/likely pathogenic germline variant, OR * Family history of exocrine pancreatic cancer in 1 affected first-degree relative and 1 second-degree relative, even in the absence of a known pathogenic/likely pathogenic germline variant, OR * Family history of exocrine pancreatic cancer in >= 3 first- and/or second-degree relatives from the same side of the family, even in the absence of a known pathogenic/likely pathogenic germline variant. OR
• Individuals who are undergoing clinically recommended pancreatic cancer surveillance

Exclusion Criteria

• Individuals with active or prior pancreatic ductal adenocarcinoma diagnosis
• Individuals with any active metastatic cancer
• Individuals who are unable to give informed consent
• Individuals who are under the age of 18 (infants, children, teenagers)
• Individuals unable to tolerate magnetic resonance imaging/magnetic resonance cholangiopancreatography and endoscopic ultrasound
• Pregnant women are unlikely to be undergoing screening procedures and will not be considered eligible but can consent to the study at a later date